- Home
- VBF vs ASMB Comparison
VBF vs ASMB Comparison
Compare VBF & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VBF
- ASMB
- Stock Information
- Founded
- VBF 1970
- ASMB 2005
- Country
- VBF United States
- ASMB United States
- Employees
- VBF N/A
- ASMB N/A
- Industry
- VBF Trusts Except Educational Religious and Charitable
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- VBF Finance
- ASMB Health Care
- Exchange
- VBF Nasdaq
- ASMB Nasdaq
- Market Cap
- VBF 177.1M
- ASMB 141.8M
- IPO Year
- VBF N/A
- ASMB 2010
- Fundamental
- Price
- VBF $15.49
- ASMB $25.44
- Analyst Decision
- VBF
- ASMB Strong Buy
- Analyst Count
- VBF 0
- ASMB 3
- Target Price
- VBF N/A
- ASMB $33.00
- AVG Volume (30 Days)
- VBF 45.5K
- ASMB 90.8K
- Earning Date
- VBF 01-01-0001
- ASMB 08-06-2025
- Dividend Yield
- VBF 5.18%
- ASMB N/A
- EPS Growth
- VBF N/A
- ASMB N/A
- EPS
- VBF N/A
- ASMB N/A
- Revenue
- VBF N/A
- ASMB $33,247,000.00
- Revenue This Year
- VBF N/A
- ASMB $0.04
- Revenue Next Year
- VBF N/A
- ASMB N/A
- P/E Ratio
- VBF N/A
- ASMB N/A
- Revenue Growth
- VBF N/A
- ASMB 54.77
- 52 Week Low
- VBF $13.68
- ASMB $7.75
- 52 Week High
- VBF $16.27
- ASMB $25.62
- Technical
- Relative Strength Index (RSI)
- VBF 52.09
- ASMB 78.89
- Support Level
- VBF $15.40
- ASMB $16.90
- Resistance Level
- VBF $15.60
- ASMB $24.71
- Average True Range (ATR)
- VBF 0.11
- ASMB 1.56
- MACD
- VBF 0.01
- ASMB 0.59
- Stochastic Oscillator
- VBF 57.35
- ASMB 97.94
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.